News and events
For information about upcoming events to support UCARE please visit our fundraising and events calendar.
Download UCARE's newsletters which detail some of the highlights and achievements in recent months.
Read the latest edition
- UCARE News 12 - Autumn 2013 (pdf file)
- UCARE News 11 - Spring 2013 (pdf file)
- UCARE News 10 - Autumn 2012 (pdf file)
- UCARE News 9 - Summer 2012 (pdf file)
- UCARE News 8 - Spring 2012 (pdf file)
- UCARE News 7 - Summer 2011 (pdf file)
- UCARE News 6 - Spring 2011 (pdf file)
- UCARE News 5 - Winter 2010 (pdf file)
- UCARE News 4 - Spring 2010 (pdf file)
- UCARE News 3 - Summer 2009 (pdf file)
- UCARE News 2 - Winter 2009 (pdf file)
- UCARE News 1 - Summer 2008 (pdf file)
For more information about our past events see also our updates page.
Breaking news: UCARE funded researchers take first step to unlocking new treatments for both prostate and breast cancer
Many of you are familiar with the work of Dr Val Macaulay and her team, and will have seen in the Summer 2014 newsletter in the Voices of UCARE a piece from Val about her research work and the importance of the UCARE funding to that work. As well as working on prostate cancer, Dr Macaulay and her team’s work also focuses on breast cancer which is funded by the Breast Cancer Campaign.
In a paper published in the journal Cancer Research, Dr Macaulay’s team used breast cancer cells grown in the lab, to find proteins that affect how well breast cancer cells are killed by IGF-1R blockers. In parallel with this work on breast cancer, Dr Macaulay’s team conducted experiments in prostate cancer. This part of the work was funded by your support of UCARE. As with breast cancer, the results showed that reducing the amount of DVL3, or blocking DVL3 with a chemical drug, made the prostate cancer cells easier to kill with IGF-1R blockers.
Valerie Berry, Development Officer at UCARE, said:
“We are very happy to have been able to support this work, which will help cancer researchers to find out which prostate cancer patients may respond to treatment with IGF-1R blockers. This work also suggests that it may be beneficial to test combinations of drugs that block DVL3 and IGF-1R.”
Dr Lisa Wilde, Director of Research at Breast Cancer Campaign, said:
“This is the first step to unlocking a new type of treatment, IGF-1R blockers, for the women with breast cancer who are most likely to benefit.”
More information is on the Breast Cancer Campaign website.
Tackling cancer in 2014
"World cancer report 2014" has raised some very alarming statistics about the future of cancer ~ however, there is still a strong case for optimism. In 2014 survival rates are much better than decades ago, with the key to successful treatment being early diagnosis and treatments.
How will we help tackle this problem? Research remains high on our agenda with the goal of personalised cancer care for patients. Helping people make improved life style choices, and to give advice on seeking early intervention is very important to UCARE and forms part of our strategy in prevention and diagnosis.
This is a window of opportunity for you to help…
Text WIND14 £10 to 70070 to donate to UCARE and make a difference today.
JustTextGiving by Vodafone
Updated clinical guidelines for prostate cancer
Many of you will have heard or read in the news that The National Institute for Health and Care Excellence (NICE) have recently updated their guidance on the diagnosis and care of men with prostate cancer.
We welcome the continued review of guidance and the updated evidence basis from which the decisions are made. This report continues to build on the development of standardised approach throughout England to diagnosing and managing men with prostate cancer. Many recommendations remain unchanged and there have been some additions which the clinical teams will need to discuss and implement.
For a detailed look at the guidance see the NICE website.
We thank, Anthony, who had testicular cancer and is a Life Model and artist Francis O’Neill for letting us use this oil on canvas painting to raise awareness for testicular cancer.
If you would like a copy or copies of this poster (either A5 or A2) please contact us.